Top

Published in:

01-01-2010

Modern Multidisciplinary Management of Brain Metastases

Authors: Sajeve S. Thomas, Erin M. Dunbar

Published in: Current Oncology Reports | Issue 1/2010

Abstract

Ideal management of brain metastases (BMs) requires simultaneous control of the existing brain metastasis (local brain control), prevention of future BMs (distant brain control), and control of the systemic cancer (systemic control). Available tools include whole brain radiation therapy (WBRT), surgery, stereotactic radiosurgery (SRS), and systemic therapies, such as chemotherapies, biologic agents, and radiosensitizing agents. Selecting the combination of these tools is highly individualized and is impacted by numerous factors involving the tumor, patient, provider, and evolving evidence. Historically, patients received WBRT, either alone or with local treatments (surgery or SRS). However, concern about the effects of WBRT, coupled with improvements in local control and survival in select patients, with the combination treatment, has led to a reconsideration of the role of WBRT. Additionally, there have been advancements in the efficacy and tolerance of systemic therapies and clarification regarding the relative risks and symptoms of tumor recurrence versus treatment complications. Thankfully, individualizing modern multidisciplinary management for patients with BMs is being aided by numerous recently completed, ongoing, and planned prospective series.

Shaffrey ME, Mut M, Asher AL, et al.: Brain metastases. Curr Probl Surg 2004, 41:665–741.CrossRefPubMed

Norden AD, Wen PY, Kesari S: Brain metastases. Curr Opin Neurol 2005, 18:654–661.PubMed

Brem SN, Nabors LB, Raizer JJ: Central nervous system cancers. National Comprehensive Cancer Guidelines. Available at http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed November 2009.

Sanoff HK, Sargent DJ, Campbell ME, et al.: Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741. J Clin Oncol 2008, 26:5721–5727.CrossRefPubMed

Mongan JP, Fadul CE, Cole BF, et al.: Brain metastases from colorectal cancer: risk factors, incidence, and the possible role of chemokines. Clin Colorectal Cancer 2009, 8: 100–105.CrossRef

Gori S, Rimondini S, De Angelis V, et al.: Central nervous system metastases in HER-2 positive metastatic breast cancer patients treated with trastuzumab: incidence, survival, and risk factors. Oncologist 2007, 12:766–773.CrossRefPubMed

Fortin D, Gendron C, Boudrias M, et al.: Enhanced chemotherapy delivery by intraarterial infusion and blood-brain barrier disruption in the treatment of cerebral metastasis. Cancer 2007, 109:751–760.CrossRefPubMed

Long DM, Winer EP: Capillary ultrastructure in human metastatic brain tumors. J Neurosurg 1979, 51:53–58.CrossRefPubMed

Zhang RD, Price JE, Fujimaki T, et al.: Differential permeability of the blood-brain barrier in experimental brain metastases produced by human neoplasms implanted into nude mice. Am J Pathol 1992, 141:1115–1124.PubMed

10.

Jain RK, Tong RT, Munn LL: Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model. Cancer Res 2007, 67:2729–2735.CrossRefPubMed

11.

Donelli MG, Zucchetti M, D'Incalci M: Do anticancer agents reach the tumor target in the human brain? Cancer Chemother Pharmacol 1992, 30:251–260.CrossRefPubMed

12.

Moscetti L, Nelli F, Felici A, et al.: Up-front chemotherapy and radiation treatment in newly diagnosed nonsmall cell lung cancer with brain metastases: survey by Outcome Research Network for Evaluation of Treatment Results in Oncology. Cancer 2007, 109:274–281.CrossRefPubMed

13.

Gaspar L, Scott C, Rotman M, et al.: Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 1997, 37:745–751.PubMed

14.

Sperduto PW, Berkey B, Gaspar LE, et al.: A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG database. Int J Radiat Oncol Biol Phys 2008, 70:510–514.PubMed

15.

Wen PY, Loeffler JS (1999) Management of brain metastases. Oncology (Williston Park). 13:941–954, 957–961; discussion 961–962, 969

16.

Koehler PJ: Use of corticosteroids in neuro-oncology. Anticancer Drugs 1995, 6:19–33.CrossRefPubMed

17.

Chuba PJ, Aronin P, Bhambhani K, et al.: Hyperbaric oxygen therapy for radiation-induced brain injury in children. Cancer 1997, 80:2005–2012.CrossRefPubMed

18.

Gonzalez J, Kumar AJ, Conrad CA, et al.: Effect of bevacizumab on radiation necrosis of the brain. Int J Radiat Oncol Biol Phys 2007, 67:323–326.PubMed

19.

Ruben JD, Dally M, Bailey M, et al.: Cerebral radiation necrosis: incidence, outcomes, and risk factors with emphasis on radiation parameters and chemotherapy. Int J Radiat Oncol Biol Phys 2006, 65:499–508.PubMed

20.

Sirven JI, Wingerchuk DM, Drazkowski JF, et al.: Seizure prophylaxis in patients with brain tumors: a meta-analysis. Mayo Clin Proc 2004, 79:1489–1494.CrossRefPubMed

21.

Tremont-Lukats IW, Ratilal BO, Armstrong T, et al.: Antiepileptic drugs for preventing seizures in people with brain tumors. Cochrane Database Syst Rev 2008:CD004424.

22.

Cairncross JG, Kim JH, Posner JB: Radiation therapy for brain metastases. Ann Neurol 1980, 7:529–541.CrossRefPubMed

23.

Nieder C, Berberich W, Schnabel K: Tumor-related prognostic factors for remission of brain metastases after radiotherapy. Int J Radiat Oncol Biol Phys 1997, 39:25–30.PubMed

24.

Schiff D, Cavaliere R: Role of fractionated radiotherapy and radiotherapy in newly diagnosed brain metastases. In ASCO Educational Book. Edited by Govindan R. Alexandria, VA: American Society of Clinical Oncology; 2009:95–99.

25.

Sawaya R, Hammoud M, Schoppa D, et al. (1998) Neurosurgical outcomes in a modern series of 400 craniotomies for treatment of parenchymal tumors. Neurosurgery, 42:1044–1055; discussion 1055–1056.CrossRefPubMed

26.••

Mueller R, Soffietti R, Abaciouglu MU, et al.: Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of 1–3 cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol 2009, 27:89s. This article discusses the long-awaited prospective results on the combination of WBRT with local treatment (surgery or SRS), including their impact on local control, neurologic symptoms, survival, and NCF.

27.

Patchell RA, Tibbs PA, Regine WF, et al.: Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA 1998, 280:1485–1489.CrossRefPubMed

28.

Andrews DW, Scott CB, Sperduto PW, et al.: Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 2004, 363:1665–1672.CrossRefPubMed

29.•

Swinson BM, Friedman WA: Linear accelerator stereotactic radiosurgery for metastatic brain tumors: 17 years of experience at the University of Florida. Neurosurgery 2008, 62:1018–1031; discussion 1031–1032. This article represents one of the largest and robust prospective datasets involving SRS for BMs.CrossRefPubMed

30.

Sawrie SM, Guthrie BL, Spencer SA, et al.: Predictors of distant brain recurrence for patients with newly diagnosed brain metastases treated with stereotactic radiosurgery alone. Int J Radiat Oncol Biol Phys 2008, 70:181–186.PubMed

31.

Patchell RA, Tibbs PA, Walsh JW, et al.: A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 1990, 322:494–500.PubMedCrossRef

32.

Vecht CJ, Haaxma-Reiche H, Noordijk EM, et al.: Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery? Ann Neurol 1993, 33:583–590.CrossRefPubMed

33.

Mintz AH, Kestle J, Rathbone MP, et al.: A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasis. Cancer 1996, 78:1470–1476.CrossRefPubMed

34.

Aoyama H, Shirato H, Tago M, et al.: Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA 2006, 295:2483–2491.CrossRefPubMed

35.

Chang EL, Wefel JS, Maor MH, et al.: A pilot study of neurocognitive function in patients with one to three new brain metastases initially treated with stereotactic radiosurgery alone. Neurosurgery 2007, 60:277–283; discussion 283–284.

36.

Meyers CA, Smith JA, Bezjak A, et al.: Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial. J Clin Oncol 2004, 22:157–165.CrossRefPubMed

37.

Gerstner ER, Fine RL: Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm. J Clin Oncol 2007, 25:2306–2312.CrossRefPubMed

38.

Kim KH, Lee J, Lee JI, et al.: Can upfront systemic chemotherapy replace stereotactic radiosurgery or whole brain radiotherapy in the treatment of non-small cell lung cancer patients with asymptomatic brain metastases? Lung Cancer 2009 Jul 8 (Epub ahead of print).

39.

Rohr U, Augustus S, Lasserre SF, et al.: Safety of bevacizumab in patients with metastases to the central nervous system [abstract]. J Clin Oncol 2009, 27:88s.

40.

Socinski MA, Langer CJ, Huang JE, et al.: Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases. J Clin Oncol 2009, 27:5255–5261.CrossRefPubMed

41.

Antonadou D, Paraskevaidis M, Sarris G, et al.: Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. J Clin Oncol 2002, 20:3644–3650.CrossRefPubMed

42.

Verger E, Gil M, Yaya R, et al.: Temozolomide and concomitant whole brain radiotherapy in patients with brain metastases: a phase II randomized trial. Int J Radiat Oncol Biol Phys 2005, 61:185–191.PubMed

43.

Addeo R, De Rosa C, Faiola V, et al.: Phase 2 trial of temozolomide using protracted low-dose and whole-brain radiotherapy for nonsmall cell lung cancer and breast cancer patients with brain metastases. Cancer 2008, 113:2524–2531.CrossRefPubMed

44.

Neuhaus T, Ko Y, Muller RP, et al.: A phase III trial of topotecan and whole brain radiation therapy for patients with CNS-metastases due to lung cancer. Br J Cancer 2009, 100:291–297.CrossRefPubMed

45.

Fiveash JB: A phase II study of radiosurgery and temozolomide for patients with one to four brain metastases. J Clin Oncol 2007, 25:2048.

46.

Dunbar E, Murad G, Keeling C: Study of temozolomide to treat newly diagnosed brain metastases [NCT00717275]. Available at http://clinicaltrials.gov/ct2/show/NCT00717275?term=erin+dunbar&rank=5. Accessed October 2009.

47.

Ma S, Xu Y, Deng Q, et al.: Treatment of brain metastasis from non-small cell lung cancer with whole brain radiotherapy and Gefitinib in a Chinese population. Lung Cancer 2009, 65:198–203.CrossRefPubMed

48.

Richards GM, Khuntia D, Mehta MP: Therapeutic management of metastatic brain tumors. Crit Rev Oncol Hematol 2007, 61:70–78.CrossRefPubMed

Title: Modern Multidisciplinary Management of Brain Metastases
Authors: Sajeve S. Thomas
Erin M. Dunbar
Publication date: 01-01-2010
Publisher: Current Science Inc.
Published in: Current Oncology Reports / Issue 1/2010
Print ISSN: 1523-3790
Electronic ISSN: 1534-6269
DOI: https://doi.org/10.1007/s11912-009-0073-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2010

The Expanding Role of Bevacizumab in the Treatment of Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer

CYP2D6 Polymorphisms and Tamoxifen Metabolism: Clinical Relevance

Biology and Therapy of Neoplastic Meningitis

Neurotoxicity of Cancer Treatment

The Increasing Use of Prophylactic Mastectomy in the Prevention of Breast Cancer

Neurologic Complications of Cancer and its Treatment

Keynote webinar | Spotlight on antibody–drug conjugates in cancer